Dividends & Buybacks ·
Enlivex reports $1.95B net income and executes 1-for-15 reverse stock split effective July 9, 2026
ENLVEnlivex Ltd.
Enlivex Ltd. filed its unaudited condensed consolidated financial statements for the six months ended June 30, 2026, reporting a net income of $1.95 billion driven by unrealized gains on its digital asset treasury and RAIN Option. The company executed a 1-for-15 reverse stock split effective July 9, 2026, reducing outstanding shares from approximately 252 million to roughly 16.8 million. Enlivex operates in the biotechnology industry, focusing on longevity therapeutics like Allocetra™ for osteoarthritis while maintaining a treasury strategy centered on decentralized prediction market assets.